Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Astellas Pharma Inc.
- Clovis Oncology, Inc.
- Johnson & Johnson Health Care Systems Inc.
- Bayer AG
- Orion Corporation
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca PLC
Browse Key Market Insights with Data Illustration:
In the News
-
Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)
-
Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.
